38 studies found for:    pkd
Show Display Options
Rank Status Study
21 Active, not recruiting A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: ADPKD Diet
22 Completed 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
23 Unknown  Clinical Trial to Slow the Progression of ADPKD
Conditions: Kidney, Polycystic;   Kidney, Polycystic, Autosomal Dominant
Intervention: Drug: anti-hypertensive medications
24 Recruiting Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Conditions: Polycystic Kidney, Type 1 Autosomal Dominant Disease;   Polycystic Kidney, Type 2 Autosomal Dominant Disease
Interventions: Drug: Sirolimus;   Drug: Placebo
25 Recruiting Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Condition: Polycystic Kidney Disease
Intervention:
26 Completed Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Polycystic Kidney, Autosomal Dominant
Intervention:
27 Completed Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes
Condition: Diabetic Kidney Disease
Intervention:
28 Terminated Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients
Condition: Infection Prophylaxis
Interventions: Drug: SAR279356;   Drug: placebo
29 Completed Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
30 Completed Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia
Condition: Sleep Initiation and Maintenance Disorders
Intervention: Drug: Eplivanserin (SR46349)
31 Completed Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine HOE901;   Drug: Insulin glargine - New formulation HOE901
32 Completed Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Condition: Healthy
Interventions: Drug: CLOPIDOGREL;   Drug: placebo
33 Completed Effect of Alirocumab SAR236553 (REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: ezetimibe;   Drug: ezetimibe placebo;   Drug: fenofibrate
34 Completed Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
35 Completed Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010);   Drug: Placebo
36 Completed Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
37 Completed Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Insulin glargine (HOE901)
38 Completed Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
Condition: Type1 Diabetes
Intervention: Drug: Insulin glargine new formulation HOE901

Show previous page of results Previous Page (1-20) Studies Shown (21-38) Next Page
Indicates status has not been verified in more than two years